Relic Technologies accepts resignation of Karthik Iyer

0 min read Updated on 13 Jun 2026, 04:34 PM

Reviewed by

Riya DScanX News Team

AI Summary

Relic Technologies accepted the resignation of Mr. Karthik Iyer as Executive Director effective June 13, 2026, due to personal and health reasons. The company disclosed the change in compliance with SEBI Listing Regulations.

*this image is generated using AI for illustrative purposes only.

Relic Technologies has accepted the resignation of Mr. Karthik Iyer as Executive Director of the company effective June 13, 2026. Mr. Iyer will also cease to be a Director of the company from the same date. The company disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and a relevant SEBI circular dated January 30, 2026.

The resignation was tendered due to personal and health reasons, as stated in the formal resignation letter addressed to the Board of Directors. Mr. Karthik Swaminathan Iyer, holding DIN 08216928, expressed his gratitude to the Board and management for their support during his tenure.

Resignation Details

Particulars	Details
Name of Director	Mr. Karthik Iyer
Designation	Executive Director
Effective Date	June 13, 2026
Reason	Personal and health reasons

The disclosure was submitted to BSE Limited by Anita Amitkumar Gupta, Company Secretary and Compliance Officer of Relic Technologies Limited.

Historical Stock Returns for Relic Technologies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-7.31%	-20.69%	-5.42%	-20.39%	-16.67%	+342.86%

Who will be appointed to replace Mr. Iyer, and how will this transition impact the company's strategic direction?

What measures will Relic Technologies implement to ensure continuity in leadership during this transition period?

How might the market react to this leadership change, and could it affect investor confidence?

Standalone Financial Performance

For the financial year ended March 31, 2026, the company reported a standalone net profit of ₹54.20 lakh, a reversal from the net loss of ₹171.87 lakh recorded in the previous year. Total standalone income for the year stood at ₹130.18 lakh, down from ₹176.35 lakh in FY25, primarily due to a lack of revenue from operations which was nil compared to ₹166.32 lakh in the prior year. Other income increased to ₹130.18 lakh from ₹10.03 lakh.

On a quarterly basis, the standalone net profit for Q4 FY26 was ₹9.49 lakh, compared to a net loss of ₹24.38 lakh in the same quarter of the previous year. Total expenses for the year reduced to ₹70.95 lakh from ₹346.49 lakh in FY25.

Consolidated Financial Performance

The consolidated financial results for the group, which includes subsidiaries Relic Pharma Limited and Truhealthy Wellness Private Limited, showed a net loss of ₹694.49 lakh for FY26, compared to a net loss of ₹148.74 lakh in the previous year. Total consolidated income for the year increased to ₹341.45 lakh from ₹204.51 lakh. Revenue from operations rose to ₹267.08 lakh from ₹197.59 lakh.

For the quarter ended March 31, 2026, the consolidated net loss was ₹293.70 lakh. The company noted that it reversed deferred tax assets created on carried forward losses during the quarter.

Metric	Standalone FY26 (₹ In Lakhs)	Standalone FY25 (₹ In Lakhs)	Consolidated FY26 (₹ In Lakhs)	Consolidated FY25 (₹ In Lakhs)
Total Income	130.18	176.35	341.45	204.51
Total Expenses	70.95	346.49	798.37	351.51
Net Profit/(Loss)	54.20	(171.87)	(694.49)	(148.74)
Earnings Per Share (Basic)	1.03	(4.77)	(13.19)	(4.13)

Key Financial Highlights

The board approved the audited standalone and consolidated financial results along with the auditors' report. D. Kothary & Co., Chartered Accountants, audited the results and issued an unmodified opinion. The paid-up equity share capital of the company increased to ₹559.12 lakh as of March 31, 2026, from ₹360.00 lakh in the previous year, following the issue of equity shares at a premium.

The company's net cash and cash equivalents decreased significantly in the standalone statement to ₹38.48 lakh as of March 31, 2026, from ₹703.76 lakh at the end of the previous year, largely due to investing and financing activities. In the consolidated statement, cash and cash equivalents stood at ₹70.05 lakh compared to ₹709.79 lakh in the prior year.

Historical Stock Returns for Relic Technologies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-7.31%	-20.69%	-5.42%	-20.39%	-16.67%	+342.86%

How will Relic Technologies rebuild its standalone revenue from operations, given that it reported nil revenue in FY26 while relying entirely on other income for profitability?

What is the strategic roadmap for subsidiaries Relic Pharma Limited and Truhealthy Wellness Private Limited to reduce the consolidated net loss, which widened nearly five-fold to ₹694.49 lakh in FY26?

With cash and cash equivalents declining sharply from ₹703.76 lakh to ₹38.48 lakh on a standalone basis, how does the company plan to manage its liquidity and fund future operations?